XCUR Stock Summary and Trading Ideas (Exicure | NASDAQ:XCUR)

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Exicure trades on the NASDAQ stock market under the symbol XCUR.

As of May 12, 2026, XCUR stock price declined to $3.24 with 7,408 million shares trading.

XCUR has a beta of -1.11, meaning it tends to be less sensitive to market movements. XCUR has a correlation of 0.03 to the broad based SPY ETF.

XCUR has a market cap of $20.65 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, XCUR traded as high as $36.00 and as low as $1.44.

The top ETF exchange traded funds that XCUR belongs to (by Net Assets): VXF, IWC, VTI.

XCUR has underperformed the market in the last year with a price return of -71.7% while the SPY ETF gained +32.1%. XCUR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.8% and -9.0%, respectively, while the SPY returned +6.9% and +3.2%, respectively.

XCUR support price is $3.21 and resistance is $3.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XCUR shares will trade within this expected range on the day.